Developing a new treatment for Mild Cognitive Impairment in Alzheimer's Disease
Preclinical and early clinical development of a GABA-A a5 PAM
This study is testing a new medication called BPN-27473 to see if it can help people with Mild Cognitive Impairment from Alzheimer's Disease by calming down certain brain areas to improve memory and thinking skills.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Agenebio, INC. NIH-funded |
| Lab location | 1 site (Baltimore, UNITED STATES) |
| Project ID | NIH-11246841 on NIH RePORTER |
What this research studies
This research focuses on advancing a new medication called BPN-27473, which is designed to help patients with Mild Cognitive Impairment due to Alzheimer's Disease. The approach involves targeting specific receptors in the brain to reduce excessive activity in areas associated with memory and cognition. By doing so, the researchers aim to improve cognitive function and slow the progression of Alzheimer's in affected individuals. The study builds on previous findings that suggest managing brain activity can lead to better memory performance.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults experiencing Mild Cognitive Impairment related to Alzheimer's Disease.
Not a fit: Patients with advanced Alzheimer's Disease or those without cognitive impairment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients suffering from Mild Cognitive Impairment due to Alzheimer's Disease, potentially improving their cognitive function and quality of life.
How similar studies have performed: Previous studies have shown promising results using similar approaches to manage hippocampal activity, indicating potential for success in this novel treatment.
Where this research is happening
Baltimore, UNITED STATES
- Agenebio, INC. — Baltimore, United States (Active)
Researchers
- Principal investigator: Payie, Kenneth G — Agenebio, INC.
- Study coordinator: Payie, Kenneth G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.